Clinical Trial

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-08-04; most recent amendment 2024-10-09.
Trial Details
NCT Number NCT04501705
Lead Sponsor Beijing Sanbo Brain Hospital
Conditions Recurrent Atypical/malignant Meningioma
Enrollment 29 participants
Start Date 2020-08-18
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-15